Pharma Mar (NASDAQ:PHMMF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Pharma Mar (NASDAQ:PHMMF) opened at 3.27 on Tuesday. Pharma Mar has a 1-year low of $2.13 and a 1-year high of $3.65. The company has a 50 day moving average of $3.05 and a 200 day moving average of $2.95. The company’s market capitalization is $722.65 million.
Get a free copy of the Zacks research report on Pharma Mar (PHMMF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com